Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted MyelomaMarco Ladetto, Antonio Palumbo, Francesco Pisani et al.|Journal of Clinical Oncology|2010Cited by 268
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapyFederica Cavallo, Antonio Palumbo, Giuseppe Milone et al.|Leukemia|2011Cited by 63
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myelomaAlessandra Larocca, Antonio Palumbo, Sara Bringhen et al.|Leukemia|2016Cited by 46
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysisStefania Oliva, Paola Omedè, Manuela Gambella et al.|Oncotarget|2016Cited by 36
LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVALMarco Ladetto, Antonio Palumbo, Simone Ferrero et al.|Blood|2011Cited by 9